SQUAMOUS LUNG CANCER WITH FGFR1 AMPLIFICATION

Clinical trials for SQUAMOUS LUNG CANCER WITH FGFR1 AMPLIFICATION explained in plain language.

Never miss a new study

Get alerted when new SQUAMOUS LUNG CANCER WITH FGFR1 AMPLIFICATION trials appear

Sign up with your email to follow new studies for SQUAMOUS LUNG CANCER WITH FGFR1 AMPLIFICATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

AI designs custom vaccines to fight lung cancer

Disease control ENROLLING_BY_INVITATION

This early-stage study is testing a personalized vaccine, Microlyvaq™, for people with advanced non-small cell lung cancer (NSCLC). The vaccine is custom-made for each patient using AI to analyze their specific tumor. It is given alongside standard chemotherapy and immunotherapy …

Matched conditions: SQUAMOUS LUNG CANCER WITH FGFR1 AMPLIFICATION

Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control

Last updated Mar 30, 2026 14:27 UTC

SQUAMOUS LUNG CANCER WITH FGFR1 AMPLIFICATION

Get alerted when new SQUAMOUS LUNG CANCER WITH FGFR1 AMPLIFICATION trials appear

AI designs custom vaccines to fight lung cancer